trending Market Intelligence /marketintelligence/en/news-insights/trending/_QamjJ9IsVdzh5u_xlK8bg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Evrofarma swings to profit in Q1

Blog

ESG hits the mainstream for European private equity sponsors

Blog

What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals

Blog

Banking Essentials Newsletter - February Edition, Part 2

Podcast

Episode 1: Origins of 451 Research - Part 1


Evrofarma swings to profit in Q1

Evrofarma SA said its normalized net income for the first quarter came to €296,250, compared with a loss of €103,130 in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin increased to 4.4% from negative 1.8% in the year-earlier period.

Total revenue rose 17.1% on an annual basis to €6.7 million from €5.7 million, and total operating expenses increased 5.7% year over year to €5.9 million from €5.6 million.

Reported net income totaled €218,000, or 2 cents per share, compared to a loss of €261,000, or a loss of 2 cents per share, in the year-earlier period.